Turn Therapeutics Inc. TTRX
10.57 USD 0.00 (+0.00%)
At closeNov 11, 2026, 4:00 PM EST
10.57 0.00 0.00%
After hours · Nov 11, 4:00 PM ET
Day range unavailable
2.57 52-week range 16.45
- YTD
- +168.27%
- 1 year
- +172.42%
News
gurufocus.com Turn Therapeutics Provides Corporate Updates and Reports Third Quarter 2026 Financial Results Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory and infectious skin d
benzinga.com Turn Therapeutics Q3 EPS $(0.21) Misses $(0.09) Estimate Turn Therapeutics (NASDAQ:TTRX) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.09) by 162.5 percent. This is a 200 percent decrease over losses of…
businesswire.com Turn Therapeutics Provides Corporate Updates and Reports Third Quarter 2026 Financial Results WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory and infectious…
businesswire.com Turn Therapeutics' GX-03 Earns “Developmental Immunology Solution of the Year” in 2026 BioTech Breakthrough Awards Program WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases,…
benzinga.com This Tesla Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday Analysts upgraded SAFE, CNOB, LMT and more.
benzinga.com This Allegion Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
benzinga.com WBB Securities Upgrades Turn Therapeutics to Hold, Maintains Price Target to $10 WBB Securities analyst Karen Sterling upgrades Turn Therapeutics (NASDAQ:TTRX) from Sell to Hold and maintains the price target from $10 to $10.
benzinga.com This Ares Management Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday Analysts initiated coverage: ARES Overweight, $150; MGEE Neutral, $76; TTRX Buy, $24; QNCX Buy, $70; EFSC Buy, $70.- benzinga.com LUCID CAPITAL MARKETS Initiates Coverage On Turn Therapeutics with Buy Rating, Announces Price Target of $24 LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Turn Therapeutics (NASDAQ:TTRX) with a Buy rating and announces Price Target of $24.
benzinga.com WBB Securities Downgrades Turn Therapeutics to Sell, Announces $10 Price Target WBB Securities analyst Karen Sterling downgrades Turn Therapeutics (NASDAQ:TTRX) from Hold to Sell and announces $10 price target.
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) shares rose 25.3% to $2.08 during Friday's after-market session. The market value of their outstanding shares is at $1.1 million. Corbus Pharmaceuticals
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Indaptus Therapeutics (NASDAQ:INDP) stock increased by 46.7% to $1.79 during Tuesday's regular session. The market value of their outstanding shares is at $162.5 million. PDS Biotechnology…
benzinga.com Turn Therapeutics Publishes Peer-Reviewed Research Of GX-03 In Life. In-vivo study showed GX-03 reduced IL-36, a key early driver of the inflammatory cascade, by approximately 50%, IL-31, a major driver of itch, by nearly 68%, and IL-4, an important inflammatory…
benzinga.com Why Is Turn Therapeutics Stock Trading Higher Today? Turn Therapeutics expanded its GX-03 Phase 2 trial after interim data supported efficacy across a broader atopic dermatitis population.
benzinga.com Turn Therapeutics Completes Comprehensive Interim Analysis Of Ongoing Adaptive Phase 2 Clinical Trial Evaluating GX-03 For Treatment Of Atopic Dermatitis Clinically meaningful efficacy observed across a broader spectrum of atopic dermatitis supports expansion of the ongoing Phase 2 program to prospectively evaluate patients across the full range of…
benzinga.com Turn Therapeutics To Present Data On Its Interim Analysis Of Its Current Adaptive Phase 2 Study Of GX-03 In Atopic Dermatitis Turn Therapeutics, Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced it will host a live webcast…- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com Turn Therapeutics Announces Interim Analysis Findings From First 50 Completed Subjects Enrolled In Ongoing Randomized, Double-Blind, Vehicle-Controlled Phase 2 Clinical Trial Evaluating GX-03 In Adults With Atopic Dermatitis 92.6% of GX-03-treated subjects achieved a 50% reduction in eczema severity in 4 weeks (EASI-50); 70.4% achieved a 75% reduction in 4 weeks (EASI-75); 44.4% achieved a 90% reduction in 4 weeks…- benzinga.com Turn Therapeutics Q1 EPS $(0.03) Misses $(0.02) Estimate Turn Therapeutics (NASDAQ:TTRX) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.02) by 50 percent. This is a 200 percent decrease over losses of…
- benzinga.com D. Boral Capital Maintains Buy on Turn Therapeutics, Maintains $8 Price Target D. Boral Capital analyst Jason Kolbert maintains Turn Therapeutics (NASDAQ:TTRX) with a Buy and maintains $8 price target.
- benzinga.com Turn Therapeutics Advances GX-03 Phase 2 Program, Expands Vaccine Pipeline; Targets Initial Commercial Revenue In 2026 Phase 2 trial of GX-03 for moderate-severe atopic dermatitis on track to complete both interim analysis and topline data in first half of 2026Appointment of Martin Dewhurst, a 30+ years McKinsey &…
- benzinga.com D. Boral Capital Initiates Coverage On Turn Therapeutics with Buy Rating, Announces Price Target of $8 D. Boral Capital analyst Jason Kolbert initiates coverage on Turn Therapeutics (NASDAQ:TTRX) with a Buy rating and announces Price Target of $8.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session - benzinga.com Turn Therapeutics Enters Into Global Supply, Development, And License Agreement With Medline Turn Therapeutics (NASDAQ:TTRX) ("Turn" or the "Company"), a clinical-stage biotechnology company developing next-generation dermatology, wound, and anti-infective therapies, today announced it has…
benzinga.com Dow Dips Over 250 Points; Delta Air Lines Posts Upbeat Earnings 
benzinga.com US Stocks Mixed; Nasdaq Falls Over 50 Points 
benzinga.com Stock Market Today: S&P 500, Nasdaq Futures Slip As Fed Minutes Signal Tariff-Related Uncertainty—PepsiCo, Delta, Levi Strauss In Focus (UPDATED) Editor’s Note: The future prices of benchmark tracking ETFs were updated in the story. U.S. stock futures fell on Thursday following Wednesday’s mixed close. Futures of major benchmark indices were…
benzinga.com Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket 
benzinga.com PepsiCo, Delta Air Lines And 3 Stocks To Watch Heading Into Thursday Stock futures mixed, investor focus on PepsiCo, Costco, and Delta earnings. Turn Therapeutics surges, while Levi Strauss reports after bell.
benzinga.com Turn Therapeutics Shares Skyrocket 134% After Hours Following Nasdaq Debut Turn Therapeutics' shares surged 134% in after-hours trading following its Nasdaq debut, despite a sharp decline during the regular session.